HHS made permanent the acting heads of two FDA centers, with Michael Davis becoming permanent director of CDER and Karim Mikhail taking over CBER. The appointments also created a new deputy commissioner role for technology and artificial intelligence, reflecting the agency’s renewed emphasis on operational continuity. Analysts described the moves as a stabilizing signal after a period of leadership turbulence tied to policy swings and staff turnover. Both permanent directors had already been serving in “caretaker” capacity, according to the FDA and HHS releases. For the biotech sector, stable center leadership affects how sponsors read the consistency of review processes—particularly for drugs and biologics that depend on predictable regulatory timelines.